IFB-088 slows disease progression in bulbar-onset ALS trial

Oral therapy IFB-088 (icerguastat) was safe and significantly slowed disease progression in certain people with amyotrophic lateral sclerosis (ALS), according to new data from a Phase 2 clinical trial. “We are very encouraged by the results we observed with IFB-088,” Pierre Miniou, CEO of IFB-088’s developer Inflectis Bioscience,…

A clinical trial that will test a noninvasive, nerve-modulating device called MyoRegulator — designed to slow disease progression in people with amyotrophic lateral sclerosis (ALS) — has been cleared to start patient enrollment in the U.S. That green light, from an Institutional Review Board, will allow Pathmaker…

People with amyotrophic lateral sclerosis (ALS) who choose invasive ventilation to help with breathing less frequently require opioids to manage their symptoms compared with ALS patients who remain on noninvasive ventilation or have no ventilatory support at all, according to a new study by researchers in Japan. Opioid use…

This afternoon, I loaded our household trash into the back of my husband’s accessible van. After opening the rear hatch and lowering the ramp, I simply dragged our three 33-gallon trash cans up the ramp to where Todd would normally park his power wheelchair, then I drove to the transfer…

Repeated traumatic brain injuries (TBIs), which happen when the brain is damaged by external impacts such as a fall or a car accident, can accelerate the onset and progression of amyotrophic lateral sclerosis (ALS) associated with mutations in the SOD1 gene, a new mouse study suggests. The effects of…

Over the past six years, I’ve welcomed over 2,000 people to the ALS News Today Forums. It’s one of my many duties as a forums co-moderator. The other things I do include being alert for spammers, adding interesting topics to spark group discussions, and answering members’ questions. Although a high…

uniQure is planning to start enrolling patients in a second dose group as part of a clinical trial testing AMT-162, its one-time gene therapy for amyotrophic lateral sclerosis (ALS) associated with mutations in the SOD1 gene. The open-label Phase 1/2 study, called EPISOD1 (NCT06100276) is intended to…

Neuropeutics has partnered with LifeArc to advance work on a small molecule therapy against TDP-43 clumping as a potential disease-modifying treatment for amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND). Studies in cellular and animal models found the candidate treatment,…

It takes longer for people with amyotrophic lateral sclerosis (ALS) who are being treated with Radicava (edaravone) to reach certain disease progression milestones, such as using a walking aid or a wheelchair, compared with those not treated with the medication. A study of real-world data also indicates the…

AB Science will launch a new Phase 3 clinical trial to test its investigational oral therapy masitinib in people with amyotrophic lateral sclerosis (ALS) whose disease is progressing normally and who haven’t completely lost physical function, according to a company update. The trial, called AB23005, will replace…